Brokerage firm Jefferies has initiated coverage on Molbio Diagnostics with a 'Buy' rating and a target price of Rs 1,600. The company, which recently listed on the stock exchanges in August 2026, has seen active interest from institutional investors. While some reports have discussed recent bulk deals involving Motilal Oswal Alternates, the primary brokerage update confirms a positive outlook based on the company's diagnostic platform.
Jefferies has initiated coverage on Molbio Diagnostics, setting a ‘Buy’ rating with a target price of Rs 1,600 per share. This move comes shortly after the company's debut on the Indian stock exchanges in August 2026, when it launched with an IPO price of Rs 807 per share. The coverage reflects investor interest in the firm's specialized healthcare technology business.
Business Model and Market Position
Molbio Diagnostics is primarily known for its Truenat portable molecular testing platform. The system is designed to provide rapid point-of-care diagnostics, which are essential for testing in regions with limited laboratory infrastructure. Currently, the platform supports testing for over 30 different diseases. A key component of the company’s revenue model is its high dependence on tuberculosis (TB) testing kits, which account for approximately 70% of its total revenue. The company’s ability to maintain growth often depends on the continued adoption of these test kits and its success in expanding its diagnostic catalog to other ailments.
Institutional Activity and Recent Market Context
There has been significant institutional movement surrounding the stock since its listing. In early October 2026, HDFC Mutual Fund increased its holding in the company, acquiring a 1.99% stake—amounting to 23 lakh shares—at a price of Rs 1,315 per share. Simultaneously, there has been selling activity from other institutional participants. Notably, Business Excellence Trust III, a fund associated with Motilal Oswal Alternates, offloaded 23.28 lakh shares in a recent bulk deal. This activity explains the high volume and market attention surrounding the stock, as various funds adjust their positions post-listing.
Risks and Monitorables for Investors
While the brokerage outlook highlights the potential of the Truenat platform, investors should remain aware of specific business risks. The company faces a high degree of customer concentration, with a large portion of its revenue tied to government contracts and a small number of top-tier clients. This concentration can impact revenue stability if contract renewals or tender timelines fluctuate. Additionally, the company’s heavy reliance on TB testing kits creates a product concentration risk. Moving forward, shareholders may track the company's ability to diversify its product portfolio beyond TB testing, the sustained execution of its international expansion plans, and the overall stability of its recurring revenue model as it navigates a volatile market environment.